These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 11422078)

  • 41. Safety of lansoprazole.
    Colin-Jones DG
    Br J Clin Pract Suppl; 1994; 75():58-61; discussion 62-6. PubMed ID: 8060803
    [No Abstract]   [Full Text] [Related]  

  • 42. Reversible edema in a male patient taking parenteral pantoprazole infusion for pyloric stenosis.
    Sennaroglu E; Karakan S; Kayatas M; Akdur S; Genc H; Karakan T; Ucler R; Ozisler C; Urun Y
    Dig Dis Sci; 2006 Jan; 51(1):121-2. PubMed ID: 16416223
    [No Abstract]   [Full Text] [Related]  

  • 43. Lansoprazole-induced hepatic dysfunction.
    García-Cortés M; Lucena MI; Andrade RJ; Romero-Gómez M; Fernández MC
    Ann Pharmacother; 2003 Nov; 37(11):1731. PubMed ID: 14626292
    [No Abstract]   [Full Text] [Related]  

  • 44. [Galactorrhea induced by lansoprazole].
    Izquierdo Prieto OM; Moreno Alía E; Rosillo González A
    Aten Primaria; 2004 Oct; 34(6):325-6. PubMed ID: 15491529
    [No Abstract]   [Full Text] [Related]  

  • 45. Pharmacokinetics and effect on caffeine metabolism of the proton pump inhibitors, omeprazole, lansoprazole, and pantoprazole.
    Andersson T; Holmberg J; Röhss K; Walan A
    Br J Clin Pharmacol; 1998 Apr; 45(4):369-75. PubMed ID: 9578184
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Lack of interaction between atazanavir and lansoprazole.
    Kosel BW; Storey SS; Collier AC
    AIDS; 2005 Mar; 19(6):637-8. PubMed ID: 15802988
    [No Abstract]   [Full Text] [Related]  

  • 47. [Drug interactions. Proton pump inhibitors II].
    Zaigler M
    Internist (Berl); 1998 Sep; 39(9):978-9. PubMed ID: 9788120
    [No Abstract]   [Full Text] [Related]  

  • 48. [Myoclonic encephalopathy associated with proton pump inhibitors].
    Boulliat J; Polard E; Colin F; Bentué-Ferrer D; Allain H
    Rev Neurol (Paris); 2004 Mar; 160(3):350-1. PubMed ID: 15037850
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Proceedings of the 2nd International Colloquium on Proton Pump Inhibitors.
    J Clin Gastroenterol; 1995; 20 Suppl 1():S1-51. PubMed ID: 7673606
    [No Abstract]   [Full Text] [Related]  

  • 50. Alternative method for administering proton-pump inhibitors through nasogastric tubes.
    Peckman HJ
    Am J Health Syst Pharm; 1999 May; 56(10):1020. PubMed ID: 10365730
    [No Abstract]   [Full Text] [Related]  

  • 51. Recurrent anaphylaxis linked to pantoprazole.
    Kollmeier AP; Eddleston J; Zuraw BL; Christiansen SC
    J Allergy Clin Immunol; 2004 Oct; 114(4):975-7. PubMed ID: 15480345
    [No Abstract]   [Full Text] [Related]  

  • 52. Lansoprazole: in the treatment of gastro-oesophageal reflux disease in children and adolescents.
    Croom KF; Scott LJ
    Drugs; 2005; 65(15):2129-35; discussion 2136-7. PubMed ID: 16225368
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Helicobacter pylori gastritis and epithelial cell proliferation in patients with reflux oesophagitis after treatment with lansoprazole.
    Berstad AE; Hatlebakk JG; Maartmann-Moe H; Berstad A; Brandtzaeg P
    Gut; 1997 Dec; 41(6):740-7. PubMed ID: 9462205
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Safety profile of Lansoprazole: the US clinical trial experience.
    Freston JW; Rose PA; Heller CA; Haber M; Jennings D
    Drug Saf; 1999 Feb; 20(2):195-205. PubMed ID: 10082075
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Suppression of Acid Secretion by Lansoprazole and its Effects on Helicobacter pylori. II. Poster presentations from the 2nd International Colloquium on Proton Pump Inhibitors. Houston, Texas, September 29, 1994.
    J Clin Gastroenterol; 1995; 20 Suppl 2():S1-135. PubMed ID: 7594319
    [No Abstract]   [Full Text] [Related]  

  • 56. Which proton pump inhibitor should we use?
    Williams CN
    Can J Gastroenterol; 1997; 11(1):29. PubMed ID: 9113794
    [No Abstract]   [Full Text] [Related]  

  • 57. Treatment with lansoprazole also induces hypertrophy of the parietal cells of the stomach.
    Stolte M; Meining A; Seifert E; Alexandridis T
    Pathol Res Pract; 2000; 196(1):9-13. PubMed ID: 10674267
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole.
    Andersson T
    Clin Pharmacokinet; 1996 Jul; 31(1):9-28. PubMed ID: 8827397
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Tetany secondary to the use of a proton-pump inhibitor.
    Subbiah V; Tayek JA
    Ann Intern Med; 2002 Aug; 137(3):219. PubMed ID: 12160379
    [No Abstract]   [Full Text] [Related]  

  • 60. Possible lansoprazole-induced eosinophilic syndrome.
    Smith JD; Chang KL; Gums JG
    Ann Pharmacother; 1998 Feb; 32(2):196-200. PubMed ID: 9496405
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.